Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03184038 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 22, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 2 sitesv17
  2. Re-verified, no change to tracked fieldsv16
  3. Primary completion date: Sep 30, 2024 to Sep 30, 2026
    • Study completion date: Sep 30, 2025 to Sep 30, 2026
    v15
  4. Phase: Phase 2 to Not applicable
    • Study sites: 3 to 2
    v14
  5. Study title shortened, about 8 words
    • Collaborators shortened, about 4 words
    v13
Show 11 earlier versionsHide 11 earlier versions
  1. Re-verified, no change to tracked fieldsv12
  2. Primary endpoints: 4 to 1v11 Show 5 more changesShow less
    • Interventions: Cognitive Assessment (Procedure), Stereotactic Body Radiation Therapy (Radiation), Stereotactic Radiosurgery (Radiation) to Cognitive Assessment (Procedure), Quality-of-Life Assessment (Other), Stereotactic Body Radiation Therapy (Radiation), Stereotactic…
    • Secondary endpoints: 1 to 7
    • Study description expanded, about 46 words
    • Eligibility criteria expanded, about 1 word
    • Collaborators expanded, about 4 words
  3. Primary completion date: Jul 2022 to Sep 30, 2024
    • Study completion date: Jul 2022 to Sep 30, 2025
    v10
  4. Primary completion date: Jul 2021 to Jul 2022v9
  5. Primary completion date: May 2021 to Jul 2021
    • Study completion date: May 2022 to Jul 2022
    v8
  6. Re-verified, no change to tracked fieldsv7
  7. Eligibility criteria shortened, about 7 wordsv6
  8. Site details revised at 1 of 3 sitesv5
  9. Enrollment target: 360 to 90v4
  10. Study sites: 2 to 3v3
  11. Study sites: 1 to 2v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.
Trial Details
NCT Number NCT03184038
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Conditions
(from sponsor)		 Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Related terms Brain Neoplasms, Neoplasm Metastasis
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov